从临床病例分析达比加群的个体化给药方案及用药监测  

Clinical Cases Analysis of Individualized Drug Administration and Drug Monitoring of Dabigatran

作　　者：祁蕙 张伟霞[2] Qi Hui;Zhang Weixia(Department of Pharmacy,Chengdu Sixth People's Hospital,Chengdu 610051,China;Department of Pharmacy,Ruijin Hospital,Shanghai Jiaotong University School of Medicine)

机构地区：[1]成都市第六人民医院药剂科,成都610051 [2]上海交通大学医学院附属瑞金医院药剂科

出　　处：《药物流行病学杂志》2020年第11期772-775,共4页Chinese Journal of Pharmacoepidemiology

摘　　要：通过对1例肾功能不全的非瓣膜性房颤患者达比加群酯给药方案的分析,结合国内外相关临床使用指南和治疗进展,总结、分析影响达比加群酯抗凝效果的相关因素,并根据实验室监测评估个体化治疗的安全性及有效性。Through analysis of dabigatran etexilone dosing regimen in a patient of non-valvular atrial fibrillation with renal insufficiency,according to the latest guidelines and treatment progress,summarized and analyzed the relevant factors affecting the anticoagulant effect of dabigatran etexilate and the laboratory monitoring to assess the safety and efficacy of individualized treatment strategies.

关 键 词：达比加群酯 肾功能不全 P-糖蛋白 活化部分凝血活酶时间 药学监护 

分 类 号：R97[医药卫生—药品]